Drug Trial Radar · NCT05553808
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
Last checked: Nov 19, 2026Latest source record: Jan 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jan 24, 2019
Primary completion
Sep 23, 2021
Study completion Sep 23, 2021
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- iTeos Belgium SA
- First posted
- Sep 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study has assessed the clinical activity of novel regimen (Feladilimab plus Docetaxel) with SOC (Docetaxel) in participants with NSCLC.
Conditions
- Neoplasms
Interventions
DocetaxelDrug
Docetaxel was administered as IV infusion.
FeladilimabDrug
Feladilimab was administered as IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Up to 2 years
Locations
43 sites in 12 countries. Site status is shown where the registry gives one.
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Caen, France
GSK Investigational Site
Nantes, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Villejuif, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Gauting, Bavaria, Germany
GSK Investigational Site
Immenhausen, Hesse, Germany
GSK Investigational Site
Leipzig, Saxony, Germany
GSK Investigational Site
Großhansdorf, Schleswig-Holstein, Germany
GSK Investigational Site
Meldola (FC), Emilia-Romagna, Italy
GSK Investigational Site
Ravenna, Emilia-Romagna, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Orbassano (TO), Piedmont, Italy
GSK Investigational Site
Maastricht, Netherlands
GSK Investigational Site
Lodz, Poland
GSK Investigational Site
Poznan, Poland
GSK Investigational Site
Warsaw, Poland
GSK Investigational Site
Bucharest, Romania
GSK Investigational Site
Craiova, Romania
GSK Investigational Site
Floreşti, Romania
GSK Investigational Site
Otopeni, Romania
GSK Investigational Site
Timișoara, Romania
GSK Investigational Site
Chelyabinsk, Russia
GSK Investigational Site
Saint Petersburg, Russia
GSK Investigational Site
Saint Petersburg, Russia
GSK Investigational Site
Cheongju-si, South Korea
GSK Investigational Site
Gyeonggi-do, South Korea
GSK Investigational Site
Seongnam, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.